Characterisation of the antifungal effects of a plant-based compound, CIN-102, on the main septal filamentous fungi involved in human pathology

• Published in: Journal of global antimicrobial resistance. 2021-06, Vol.25, p.171-180
• Main Authors: D'Agostino, Maurine, Tesse, Nicolas, Lavergne, Rose Anne, Pape, Patrice Le, Bouchara, Jean Philippe, Frippiat, Jean Pol, Machouart, Marie, Debourgogne, Anne
• Format: Article
• Language: English
• Subjects: Antifungal; Aspergillus; Fungi; Fusarium; Life Sciences; Microbiology and Parasitology; Mycology; Parasitology; Scedosporium
• ISSN: 2213-7165; 2213-7173
• DOI: 10.1016/j.jgar.2021.03.017

•CIN-102 has antifungal activity against the genera Aspergillus, Scedosporium and Fusarium.•The various strains tested had no phenotypes of resistance against CIN-102.•CIN-102 shows an effect on spore germination and fungal growth.•The post-antifungal effect is important with CIN-102. Today, the increase of invasive fungal infections and the emergence of resistant strains are observed in medical practice. New antifungals are expected, and the plant world offers a panel of potentially active molecules. CIN-102 is a mixture of seven different compounds of plant origin developed from the formulation of cinnamon essential oil. The in vitro activity of CIN-102 was characterised against Aspergillus spp., Fusarium spp. and Scedosporium spp. by studying the minimum inhibitory concentration (MIC), inoculum effect, germination inhibition, fungal growth, post-antifungal effect (PAFE) and synergy. MICs determined for the three genera followed a unimodal distribution and their mean values ranged from 62–250 μg/mL. CIN-102 demonstrated an inoculum effect similar to voriconazole and amphotericin B, 100% inhibition of spore germination and a PAFE. CIN-102 has significant activity against filamentous fungi involved in human pathologies and should be further explored as a potential new treatment. Other studies regarding its mechanisms of action as well as animal investigations are awaited.